Synthetic Biologics
OverviewSuggest Edit
Synthetic Biologics is a late-stage clinical company developing therapeutics designed to preserve the microbiome. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, it is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.
| Type | Public | |
| Founded | 2001 | |
| HQ | Rockville, US | Map |
| Website | syntheticbiologics.com |
Recent NewsAll News
- Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019
- Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
- Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results
- Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018
Latest Updates
| Employees (est.) (Feb 2019) | 13 | (-45%) |
| Share Price (Aug 2018) | $2.6 | (-8%) |
Key People/Management at Synthetic Biologics
Steven Shallcross
Interim CEO, Chief Financial Officer, Treasurer and Secretary
Joseph Sliman
Chief Medical Officer
Michael Kaleko
Senior Vice President, Research & Development
Raymond D. Stapleton
Senior Vice President, Manufacturing
Deb Mathews
Vice President, Medical Affairs
Synthetic Biologics Office Locations
Synthetic Biologics has an office in Rockville
Rockville, US (HQ)
9605 Medical Center Dr #270
Synthetic Biologics Financials and Metrics
Synthetic Biologics Revenue
| USD | |
|---|---|
Net income (FY, 2018) | (13.4m) |
EBIT (FY, 2018) | (17.6m) |
Market capitalization (16-Aug-2018) | 276.8k |
Closing stock price (16-Aug-2018) | 2.6 |
Cash (31-Dec-2018) | 28.9m |
Synthetic Biologics's current market capitalization is $276.8 k.
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.9m | 1.1m | 1.8m | 1.2m | 1.7m | 2.2m | 1.6m | 2.4m | 2.1m | 2.1m | 2.1m | 1.7m | 1.6m | 1.4m |
R&D expense | 1.5m | 2.7m | 2.8m | 3.7m | 6.5m | 7.5m | 10.0m | 8.2m | 7.2m | 7.1m | 6.1m | 4.1m | 3.4m | 3.6m |
Operating expense total | 3.4m | 3.8m | 4.7m | 4.9m | 8.2m | 9.7m | 11.7m | 10.6m | 9.3m | 9.2m | 8.1m | 5.8m | 5.0m | 5.0m |
EBIT | (3.4m) | (3.8m) | (4.7m) | (4.9m) | (8.2m) | (9.7m) | (11.6m) | (10.6m) | (9.3m) | (9.2m) | (8.1m) | (5.8m) | (5.0m) | (5.0m) |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 5.1m | 11.2m | 7.8m | 3.3m | 12.0m | 4.8m | 31.8m | 15.1m | 10.0m | 4.5m | 13.5m | 21.1m | 11.0m | 7.1m |
Current Assets | 6.8m | 12.5m | 9.2m | 4.7m | 13.6m | 11.7m | 42.1m | 22.2m | 15.8m | 7.6m | 16.8m | 22.3m | 11.6m | 7.7m |
PP&E | 157.0k | 38.0k | 51.0k | 67.0k | 75.0k | 107.0k | 483.0k | 501.0k | 482.0k | 582.0k | 859.0k | 943.0k | 801.0k | 731.0k |
Total Assets | 7.0m | 12.5m | 9.3m | 4.7m | 13.7m | 11.8m | 42.6m | 22.7m | 16.3m | 8.2m | 17.7m | 23.3m | 12.5m | 8.4m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (8.1m) | (3.8m) | (8.4m) | (13.3m) | (12.4m) | (26.0m) | (33.5m) | (11.1m) | (16.8m) | (8.5m) | (3.1m) | (18.3m) | (2.3m) | (6.5m) |
Depreciation and Amortization | 33.0k | 3.0k | 7.0k | 13.0k | 8.0k | 19.0k | 39.0k | 37.0k | 57.0k | 57.0k | 172.0k | 71.0k | 141.0k | |
Accounts Payable | 189.0k | 631.0k | 937.0k | 731.0k | 563.0k | 7.7m | 5.0m | 184.0k | 143.0k | 4.2m | 1.8m | (895.0k) | (527.0k) | (803.0k) |
Cash From Operating Activities | (5.0m) | (3.5m) | (6.8m) | (11.3m) | (5.5m) | (12.7m) | (27.9m) | (5.7m) | (11.5m) | (6.0m) | (16.3m) | (6.1m) | (10.4m) |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 2.1 x |
Synthetic Biologics Online and Social Media Presence
1.32k Twitter followers
Synthetic Biologics has 1.32k Twitter Followers. The number of followers has decreased 0.4% month over month and decreased 0.7% quarter over quarter
Synthetic Biologics News and Updates
February 19, 2019
Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019
ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial...
November 21, 2018
Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an...
November 08, 2018
Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results
ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial ...
October 30, 2018
Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018
ROCKVILLE, Md., Oct. 30, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its...
October 15, 2018
Synthetic Biologics Announces Closing of $18,639,000 Public Offering
ROCKVILLE, Md., Oct. 15, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN) ("Synthetic Biologics" or the "Company"), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients,...
September 06, 2018
Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C
ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced it has entered into an agreement with...
 Synthetic Biologics Frequently Asked Questions
When was Synthetic Biologics founded?
Synthetic Biologics was founded in 2001.
Who are Synthetic Biologics key executives?
Synthetic Biologics's key executives are Steven Shallcross, Joseph Sliman and Michael Kaleko.
How many employees does Synthetic Biologics have?
Synthetic Biologics has 13 employees.
Who are Synthetic Biologics competitors?
Competitors of Synthetic Biologics include Otonomy, Biogen and Shire.
Where is Synthetic Biologics headquarters?
Synthetic Biologics headquarters is located at 9605 Medical Center Dr #270, Rockville.
Where are Synthetic Biologics offices?
Synthetic Biologics has an office in Rockville.
How many offices does Synthetic Biologics have?
Synthetic Biologics has 1 office.